Cladribine

December 11, 2017December 14, 2017

Australia Approves Shorter Mavenclad Treatment Regimen for Relapsing-Remitting MS

News

Australia has approved a shorter treatment regimen of Merck’s Mavenclad for relapsing-remitting multiple sclerosis. The Therapeutic Goods Administration authorized 20-day courses of the cladribine tablet form of the medication once ... Read more

December 6, 2017December 7, 2017

Health Canada Approves Merck’s Mavenclad to Treat RRMS

News

Canadians with relapsing-remitting multiple sclerosis can now receive Merck’s Mavenclad, now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay ... Read more

November 28, 2017November 30, 2017

European Neurologists Ready to Use Both Mavenclad and Ocrevus, Survey Shows

News

Mavenclad has become the multiple sclerosis therapy of choice for one in five neurologists in Germany and the United Kingdom, according to a Spherix Global Insights survey. Meanwhile, many ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Mavenclad Is ‘Smart’ Therapy for Active Relapsing MS, Researcher Says

News

Mavenclad (cladribine tablets), an oral therapy by Merck that’s approved to treat people with active relapsing multiple sclerosis in much of Europe, is a “smart therapy” that is showing ... Read more

October 20, 2017October 23, 2017

#MSParis2017 – Mavenclad Reduces Relapses, Prevents New Lesions in Many RRMS Patients, Presentations Will Show

News

Mavenclad reduced multiple sclerosis relapses by 79 percent and prevented the development of additional inflammatory lesions in 84 percent of patients with high disease activity, according ... Read more

August 29, 2017August 30, 2017

Merck’s Mavenclad, an Oral Therapy for Relapsing MS, Approved in European Union

News

The European Commission has approved Merck KGaA’s Mavenclad (cladribine tablets) to treat highly active relapsing forms of multiple sclerosis (MS). The Aug. 25 decision in Brussels marks the first ... Read more

August 28, 2017August 27, 2017

MS News that Caught My Eye This Week: Hippotherapy, Smartphone Research, and the Military

Columns, The MS Wire - A Column by Ed Tobias

Horseback Riding Plus Standard Care Can Help MS Patients Improve Balance, Other Symptoms Absolutely, it can. I don’t need to read this study to know that ... Read more

August 22, 2017August 23, 2017

Mavenclad Improves Relapsing MS Patients’ Quality of Life, Independent U.K. Study Finds

News

Merck’s Mavenclad tablets significantly improve quality of life among relapsing multiple sclerosis patients while reducing the number of relapses, according to new analyses of previously unpublished ... Read more

July 7, 2017July 11, 2017

Mavenclad Reduces MS Relapses by Reseting the Immune System

News

New analyses of how Merck’s Mavenclad (cladribine tablets) act to treat relapsing multiple sclerosis (MS) give researchers an entirely new picture of immune processes leading to ... Read more

May 30, 2017May 30, 2017

#CMSC17 – Cladribine Reduced Annual MS Relapse Rate by 55% to 57%, Trials Show

News

Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, according to clinical trials. EMD Serono, a ... Read more

February 14, 2017February 20, 2017

Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds

News

EMD Soreno has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients ... Read more

September 19, 2016September 19, 2016

#ECTRIMS2016 – Data on Merck Treatment for Relapsing MS, Cladribine Tablets, Show Long-Term Benefit

News

Merck recently presented new efficacy data from its three Phase 3 clinical trials, showing that a relatively short course of treatment with Cladribine tablets led to long-term reductions in annualized ... Read more

July 20, 2016July 20, 2016

Merck KGaA’s Investigational MS Therapy Cladribine Gets EMA Marketing Authorization Application Review

News

Merck KGaA, Darmstadt, Germany recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the company’s investigational product Cladribine Tablets as ... Read more

October 9, 2015October 9, 2015

Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence

Multiple Sclerosis News, News

A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients ... Read more

September 14, 2015September 14, 2015

Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy

News

Merck recently reported its intention to file for European registration of its product candidate for relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the ... Read more